A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
A Phase Ill Randomized Controlled Clinical Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice as Second Line Treatment in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma After Failure of PD-1/PD-L1 Monoclonal Antibody in Combination With Platinum-based Chemotherapy
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Sa Xiao, PHD
- Phone Number: +8615013238943
- Email: xiaosa@baili-pharm.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China
- Beijing Cancer Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Voluntarily sign the informed consent and follow the requirements of the protocol;
- Age ≥18 years old;
- Expected survival time ≥3 months;
- Patients with recurrent or metastatic esophageal squamous cell carcinoma confirmed by histology or cytology;
- Consent to provide archival tumor tissue samples or fresh tissue samples of primary or metastatic lesions within 3 years;
- Must have at least one measurable lesion according to RECIST v1.1 definition;
- ECOG 0 or 1;
- Toxicity of previous antineoplastic therapy has returned to ≤ grade 1 defined by NCI-CTCAE v5.0;
- No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
- No blood transfusion and no use of any cell growth factor drugs were allowed within 14 days before randomization, and the level of organ function had to be adequate;
- Urine protein ≤2+ or < 1000mg/24h;
- A serum pregnancy test must be performed within 7 days before the start of treatment for premenopausal women who are likely to have children, and the result must be negative and must not be lactating; All enrolled patients should take adequate barrier contraception during the entire treatment cycle and for 6 months after the end of treatment.
Exclusion Criteria:
- Chemotherapy, targeted therapy, biological therapy, etc., had been used within 4 weeks or 5 half-lives before randomization, and palliative radiotherapy and modern traditional Chinese medicine preparations approved by NMPA had been used within 2 weeks;
- Patients with recurrent esophageal squamous cell carcinoma suitable for radical local treatment should be excluded;
- Frontline received ADCs with topoisomerase I inhibitors as toxins;
- History of severe heart disease and cerebrovascular disease;
- Prolonged QT interval, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
- diagnosed with active malignancy within 3 years before randomization;
- Hypertension poorly controlled by two antihypertensive drugs;
- patients with poor glycemic control;
- present with grade ≥1 radiation pneumonitis according to the RTOG/EORTC definition; A previous history of interstitial lung disease (ILD) or a suspicion of such disease on imaging during screening;
- Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;
- patients with active central nervous system metastases;
- Severe infections within 4 weeks before randomization; Evidence of pulmonary infection or active pulmonary inflammation within 2 weeks before randomization;
- patients with massive or symptomatic effusions or poorly controlled effusions;
- Imaging examination showed that the tumor had invaded or wrapped around the large blood vessels in the abdomen, chest, neck, and pharynx;
- serious unhealed wounds, ulcers, or fractures, or clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
- patients with inflammatory bowel disease, extensive bowel resection history, immune enteritis history, intestinal obstruction or chronic diarrhea;
- patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;
- had a history of autologous or allogeneic stem cell transplantation;
- Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;
- a history of severe neurological or psychiatric illness;
- received other unmarketed investigational drugs or treatments within 4 weeks before randomization;
- subjects scheduled for vaccination or who received live vaccine within 28 days before study randomization;
- Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Experimental Group
Participants receive BL-B01D1 as intravenous infusion for the first cycle (3 weeks).
Participants with clinical benefit could receive additional treatment for more cycles.
The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
|
Administration by intravenous infusion
Other Names:
|
|
Experimental: Control group
Participants receive Irinotecan or paclitaxel or docetaxel in the first cycle (3 weeks).
Participants with clinical benefit could receive additional treatment for more cycles.
The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
|
Administration by intravenous infusion
Administration by intravenous infusion
Administration by intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall survival (OS)
Time Frame: Up to approximately 24 months
|
Overall survival (OS) is defined as the time between the subject's randomization date and subject's death.
|
Up to approximately 24 months
|
|
Progression-free survival (PFS)
Time Frame: Up to approximately 24 months
|
Progression-free survival (PFS) as assessed by BIRC is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death.
|
Up to approximately 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cmax
Time Frame: Up to approximately 24 months
|
Maximum serum concentration (Cmax) of BL-B01D1 will be investigated.
|
Up to approximately 24 months
|
|
T1/2
Time Frame: Up to approximately 24 months
|
Half-life (T1/2) of BL-B01D1 will be investigated.
|
Up to approximately 24 months
|
|
Objective Response Rate (ORR)
Time Frame: Up to approximately 24 months
|
Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS).
|
Up to approximately 24 months
|
|
Disease Control Rate (DCR)
Time Frame: Up to approximately 24 months
|
Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria.
|
Up to approximately 24 months
|
|
Duration of Response (DOR)
Time Frame: Up to approximately 24 months
|
Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death.
|
Up to approximately 24 months
|
|
Treatment Emergent Adverse Event (TEAE)
Time Frame: Up to approximately 24 months
|
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1.
The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1.
|
Up to approximately 24 months
|
|
Anti-drug antibody (ADA)
Time Frame: Up to approximately 24 months
|
Frequency of anti-BL-B01D1 antibody (ADA) will be investigated.
|
Up to approximately 24 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Lin Shen, PHD, Peking University Cancer Hospital & Institute
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Neoplasms by Histologic Type
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Digestive System Diseases
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Neoplasms, Glandular and Epithelial
- Esophageal Diseases
- Carcinoma
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Organic Chemicals
- Heterocyclic Compounds
- Hydrocarbons
- Cycloparaffins
- Hydrocarbons, Alicyclic
- Hydrocarbons, Cyclic
- Terpenes
- Camptothecin
- Alkaloids
- Taxoids
- Cyclodecanes
- Diterpenes
- Docetaxel
- Irinotecan
- Paclitaxel
Other Study ID Numbers
Other Study ID Numbers
- BL-B01D1-305
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.